Delivery of biologics in cardiovascular regenerative medicine

J. Bartunek, W. Sherman, M. Vanderheyden, F. Fernandez-Aviles, W. Wijns, Andre Terzic

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Stem cell-based cardiovascular regenerative medicine offers the next frontier of therapy through delivery of progenitor cells to achieve structural and functional repair of the myocardium. Initial clinical experience indicates that such therapy is feasible and safe, yet structural and functional benefits remain rather modest. A common pitfall in all studies is the very low rate of cell retention by the recipient myocardial tissue. This limitation warrants lead optimization so as to improve the outcome of stem cell delivery.

Original languageEnglish (US)
Pages (from-to)548-552
Number of pages5
JournalClinical Pharmacology and Therapeutics
Volume85
Issue number5
DOIs
StatePublished - May 2009

Fingerprint

Regenerative Medicine
Biological Products
Stem Cells
Myocardium
Therapeutics

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Bartunek, J., Sherman, W., Vanderheyden, M., Fernandez-Aviles, F., Wijns, W., & Terzic, A. (2009). Delivery of biologics in cardiovascular regenerative medicine. Clinical Pharmacology and Therapeutics, 85(5), 548-552. https://doi.org/10.1038/clpt.2008.295

Delivery of biologics in cardiovascular regenerative medicine. / Bartunek, J.; Sherman, W.; Vanderheyden, M.; Fernandez-Aviles, F.; Wijns, W.; Terzic, Andre.

In: Clinical Pharmacology and Therapeutics, Vol. 85, No. 5, 05.2009, p. 548-552.

Research output: Contribution to journalArticle

Bartunek, J, Sherman, W, Vanderheyden, M, Fernandez-Aviles, F, Wijns, W & Terzic, A 2009, 'Delivery of biologics in cardiovascular regenerative medicine', Clinical Pharmacology and Therapeutics, vol. 85, no. 5, pp. 548-552. https://doi.org/10.1038/clpt.2008.295
Bartunek, J. ; Sherman, W. ; Vanderheyden, M. ; Fernandez-Aviles, F. ; Wijns, W. ; Terzic, Andre. / Delivery of biologics in cardiovascular regenerative medicine. In: Clinical Pharmacology and Therapeutics. 2009 ; Vol. 85, No. 5. pp. 548-552.
@article{cf8c54a6fea142369f8cc9133eec690a,
title = "Delivery of biologics in cardiovascular regenerative medicine",
abstract = "Stem cell-based cardiovascular regenerative medicine offers the next frontier of therapy through delivery of progenitor cells to achieve structural and functional repair of the myocardium. Initial clinical experience indicates that such therapy is feasible and safe, yet structural and functional benefits remain rather modest. A common pitfall in all studies is the very low rate of cell retention by the recipient myocardial tissue. This limitation warrants lead optimization so as to improve the outcome of stem cell delivery.",
author = "J. Bartunek and W. Sherman and M. Vanderheyden and F. Fernandez-Aviles and W. Wijns and Andre Terzic",
year = "2009",
month = "5",
doi = "10.1038/clpt.2008.295",
language = "English (US)",
volume = "85",
pages = "548--552",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Delivery of biologics in cardiovascular regenerative medicine

AU - Bartunek, J.

AU - Sherman, W.

AU - Vanderheyden, M.

AU - Fernandez-Aviles, F.

AU - Wijns, W.

AU - Terzic, Andre

PY - 2009/5

Y1 - 2009/5

N2 - Stem cell-based cardiovascular regenerative medicine offers the next frontier of therapy through delivery of progenitor cells to achieve structural and functional repair of the myocardium. Initial clinical experience indicates that such therapy is feasible and safe, yet structural and functional benefits remain rather modest. A common pitfall in all studies is the very low rate of cell retention by the recipient myocardial tissue. This limitation warrants lead optimization so as to improve the outcome of stem cell delivery.

AB - Stem cell-based cardiovascular regenerative medicine offers the next frontier of therapy through delivery of progenitor cells to achieve structural and functional repair of the myocardium. Initial clinical experience indicates that such therapy is feasible and safe, yet structural and functional benefits remain rather modest. A common pitfall in all studies is the very low rate of cell retention by the recipient myocardial tissue. This limitation warrants lead optimization so as to improve the outcome of stem cell delivery.

UR - http://www.scopus.com/inward/record.url?scp=67349247807&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349247807&partnerID=8YFLogxK

U2 - 10.1038/clpt.2008.295

DO - 10.1038/clpt.2008.295

M3 - Article

VL - 85

SP - 548

EP - 552

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 5

ER -